Charles River Laboratories Faces Analyst Scrutiny Amid Stock Decline

2 min read | October 22, 2024 09:20 AM PDT | By Team Kalkine Media

Google News:

Charles River Laboratories Faces Analyst Scrutiny Amid Stock Decline — Image source: shutterstock

Recent News

Why Moderna Is Capturing Market Attention Again?

Eli Lilly Coverage Buzz Keeps Healthcare Market Attention High

Sandisk Gains Attention As an AI-Driven Growth Stock

Why Micron Technology Is Benefiting From the AI Growth Wave?

Make Kalkine Media
My Trusted Source

Headlines

Charles River Laboratories Faces Decline Amid Analyst Downgrades

Stock Performance Reflects Mixed Analyst Sentiment

Adjustments in Price Targets Impact CRL's Recent Trading

Charles River Laboratories International (NYSE:CRL) saw a 4.9% decline in its stock price during Tuesday's trading session. The stock reached a low of $180.75 before closing at $185.43, with approximately 783,084 shares exchanged, surpassing its usual trading volume.

Several research firms have recently adjusted their outlook on CRL. Redburn Atlantic began coverage on the company with a less favorable view, while Bank of America shifted its rating to a neutral stance. They also adjusted their price objectives in light of these changes. Goldman Sachs, similarly, lowered its target for the stock and reiterated its view, echoing the caution surrounding CRL's future performance.

Other firms like Evercore ISI downgraded their rating, and Barclays also reduced their price objective, indicating a broader trend of reevaluation among analysts. Despite the mixed ratings, a majority of the firms still hold a cautious perspective on CRL.

While the stock's performance has attracted attention, the broader market sentiment around Charles River Laboratories remains divided. Analysts are reflecting on the company’s positioning amid these recent shifts, making it a focal point for traders keeping an eye on the healthcare and research sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.